ÎÚÑ»´«Ã½

Anthony Leung, a scientist and an inventor, is an expert in the area of RNA, ADP-ribosylation, and proteomics. Anthony started his lab in 2011 as an assistant professor and is currently a tenured professor in the Department of Biochemistry and Molecular Biology at Johns Hopkins University. Funded by the Idea Award from the Department of Defense Breast Cancer Research Program, Anthony developed a novel non-biased technique to identify the sites of ADP-ribosylation, which is a technical breakthrough in the field. He has since been recognized with numerous accolades: Top 5 Agilent Early Career Professor (2013), the Inaugural Johns Hopkins Catalyst Award (2015), Research Scholar Award from the American Cancer Society (2016), and Top 10 Finalist for the American Society of Cell Biology–Gibco Emerging Leader Prize (2016). Anthony has authored over 40 peer-reviewed publications, has been invited to write book chapters, and has reviewed articles.

Anthony D. So, MD, MPA, is distinguished professor of the practice and founding director of the . Based in Health Systems in the Department of International Health, the IDEA Initiative fosters innovation and the design of systems that better enable access and impact of health technologies, particularly for those in need due to disease and disadvantage. The IDEA Initiative also currently serves as the , comprised of civil society groups and the South Centre—an intergovernmental think tank of 55 developing countries. Professor So served as Co-Convener of the UN Interagency Coordination Group on Antimicrobial Resistance, delivering its recommendations to the UN Secretary-General in 2019, and was a member of the Expert Advisory Group for the UN Secretary-General’s High-Level Panel on Access to Medicines. He co-chaired a technical working group for the 2021 WHO Fair Pricing Forum, served on the Technical Advisory Group of WHO’s COVID-19 Technology Access Pool, and currently is part of the WHO’s Market Access to Vaccines Technical Advisory Group. He was part of the Chatham House Working Group on New Business Models for Antibiotics and was a member of the Institute of Medicine’s Committee on Accelerating Rare Disease Research and Orphan Product Development. Professor So also chairs the School’s Graduate Medical Education Committee, supporting its medical residency programs in occupational and environmental medicine and general preventive medicine.

Antonio Bandeira Rodrigues is a Public Health MD resident and MPH candidate at Johns Hopkins University who is committed to advancing healthcare through innovation and compassionate leadership. He also serves as President of the Student AI Society. Previously, as a clinical journeys manager, he generated thousands of telemedicine appointments in mental health, nutrition, and elderly care, showcasing strong leadership, project management, and communication skills.

Bonnie Koo is an MPH/MBA candidate at the Johns ÎÚÑ»´«Ã½ and Carey Business School. She has over 13 years of experience across digital health, pharmaceuticals, and hospital systems, with a clinical background as a surgical and intensive care pharmacist in the United Kingdom. Her work includes business development in the pharmaceutical industry and commercialization of a digital biomarker health tech startup in the United States. At Johns Hopkins, she mentors early-stage ventures through the Fuel Accelerator at the Pava Center for Entrepreneurship. Her interests focus on translating healthcare innovation into scalable, real-world solutions by bridging clinical insight with commercial strategy.

The Jenkins-Lord Laboratory investigates how social and environmental risk factors contribute to breast cancer etiology and tumor biology, with a focus on understanding the molecular mechanisms underlying aggressive subtypes. Its research explores therapeutic strategies to overcome treatment resistance in both ER-positive and ER-negative breast cancers and examines how social determinants of health influence cancer biology and survivorship. By integrating genetic, epigenetic, and socio-environmental data, the lab aims to uncover drivers of cancer development and progression to ultimately improve outcomes for all patients.

Dr. Alexander is a Professor of Epidemiology and Medicine at the Johns ÎÚÑ»´«Ã½, where he serves as founding co-Director of the Center for Drug Safety and Effectiveness and Principal Investigator of the Johns Hopkins-FDA Center of Excellence in Regulatory Science and Innovation (JH-CERSI). He is a practicing general internist and pharmacoepidemiologist and is internationally recognized for his research examining prescription drug utilization, safety, and effectiveness. The author of over 375 scientific articles and book chapters—many of which have focused on the epidemiology of the opioid epidemic—he has published regularly in leading scientific journals and testified in front of expert bodies, including the U.S. House of Representatives and U.S. Senate. Dr. Alexander also serves on several editorial and advisory boards and is a frequent speaker on pharmaceutical utilization and policy. He received his B.A. cum laude from the University of Pennsylvania, an MD from Case Western Reserve University, and a Master of Science from the University of Chicago.

Dominick Shattuck is a cutting-edge researcher for public health topics, including masculinity, gender, reproductive health, COVID-19, and HIV. He has led groundbreaking studies and implementation projects that engage men and women, couples, and adolescents around their reproductive health and has pioneered programmatic content based on this expertise. Dominick implemented the first trial of male engagement in reproductive health in Malawi, scaled-up vasectomy services nationally in Rwanda, and designed the first efficacy study of a mobile application as a family planning method (the Dot Study). His work spans traditional social behavior change approaches to online and mobile technology integration. A Community Psychologist, Dominick's approach emphasizes the use of mixed-methods research that triangulates the perspectives of providers, beneficiaries, and policymakers.

Jeffrey Hardesty is an Assistant Scientist in the Department of Health, Behavior, and Society. He received his Master of Public Health degree with a concentration in Epidemiology and Biostatistics from the Johns ÎÚÑ»´«Ã½. His work at the Institute for Global Tobacco Control focuses on the potential benefits and unintended consequences of domestic and international e-cigarette and tobacco policies. His current projects include the Vaping and Patterns of E-cigarette use Research Study (VAPER Study)—a prospective cohort study of e-cigarette users in the U.S. He has authored state-of-the-evidence reports on raising the minimum age of purchase of tobacco products from 18 to 21, and banning or restricting flavored tobacco products. His past work focused on pictorial health warning labels in China and Indonesia.

Johannes Thrul's work focuses on mobile health (mHealth) research to study substance use, mental health, and digital well-being. He also uses technology, including smartphones and social media, to develop, test, and deliver interventions to prevent and treat substance use and mental health disorders.

John Muschelli studies how biostatistics and data science can use neuroimaging and accelerometry data to improve clinical practice. As part of the ITC, John aims to uplift BSPH investigators’ work so that it gains recognition and looks for opportunities to commercialize and translate research to the industry whenever possible. John sees opportunities for faculty to create products or services from recent shifts in algorithmic work and seeks to facilitate this process. John’s cross-department work on the Faculty Senate, his brief stint in a startup, and previous applications with Tech Transfer will help him support others to progress in the industry.

Dr. Ehsani uses policy and behavioral research to prevent motor vehicle crashes and advance the health-promoting aspects of transportation. Using experimental, observational, and population-based methods, his research is focused on identifying policies that advance the safety and equity of the transportation system. Examples of his work include the effectiveness of licensing systems for teen drivers and distracted driving policies, naturalistic driving studies that examine individual-level driver behavior, and the impact of new mobility products and services (including bike-share, e-scooters, and autonomous shuttles) on cities. He currently serves on the Academic Advisory Council of PAVE (Partners for Automated Vehicle Education).

Mei-Li Hey, MEng, is a first-year doctoral student in the Department of Environmental Health and Engineering. Advised by Dr. Carsten Prasse, she is in the Environmental, Sustainability, Resilience, and Health track. She earned a Master of Engineering degree from the University of California, Los Angeles, and has spent the past six years in the aerospace sector working as a mechanical design engineer on the James Webb Space Telescope. In 2020, she founded Atwero, a nonprofit that stemmed from research on access to improved sanitation facilities in Sub-Saharan Africa conducted while earning her undergraduate degree. Atwero designs and manufactures pit latrine assistive devices for persons with disabilities and operates out of Uganda.

Dr. Radamés J.B. Cordero is a Research Professor and the Gilbert Otto Endowed Professor for Innovation and Entrepreneurship. His research explores how fungi adapt and survive in extreme environments—including outer space—a field known as astromycology, with active collaborations with NASA and the Department of Defense. Dr. Cordero is also the founder of MelaTech, a biotechnology company developing melanin-based materials for diverse applications. He has authored over 70 peer-reviewed publications and is the inventor of three approved patents. Committed to translational science, Dr. Cordero trains students to conduct rigorous research with purpose—developing discoveries that leave the lab and solve real-world problems today.

Sara C. Woodward has been working in Johns Hopkins University development for 9 years and is currently the Development Manager in the Department of International Health. In her role, she has implemented a new development program and has been working to grow a long-term sustainable funding strategy around department priorities using a combined human-centered design and development donor process approach. Her areas of expertise include creating and managing pipelines, increasing engagement and stewardship opportunities with funders, developing new funding opportunities and giving mechanisms, working with communications to create content through a donor lens, and facilitating increased giving through relationship building with donors, partners, faculty, staff, and students. Sara is an alumna of The Peabody Conservatory at Johns Hopkins University, where she earned dual master's degrees in Opera and Historic Performance Practice. She has worked for 20+ years as a classical singer specializing in music written before 1750.

Thomas has a background in clinical and experimental pharmacology and toxicology, which has been documented in more than 730 publications. Previous work centers on the immune recognition of bacteria, including pyrogen testing and the induced inflammatory response. In experimental and clinical approaches, he studied the pharmacological modulation of these responses. Besides his directorship for the Center for Alternatives to Animal Testing (CAAT), Thomas established a laboratory for developmental neurotoxicity research based on genomics and metabolomics, developed standardized Brain Organoids and the Organoid Intelligence (OI) initiative. and the respective technologies were made available by a Thought-Leader Award from Agilent. He initiated the Evidence-based Toxicology Collaboration, the Microphysiological Systems World Summit series, the Green Toxicology program and most recently an ToxAIcology program as well as the Human Exposome Moonshot initiative. Thomas has led a technology transfer center (STZ InPuT) at the University of Konstanz, Germany, which managed 108 contracts with companies in 8 countries in six years. He founded Organome LLC as a spin-off out of JHU, which merged into AxoSim, New Orleans, where he serves as Consulting VP of Scientific Affairs. He consults a number of biotech, CRO and pharmaceutical companies. He is the founder and (co-)owner of two not-for-profit LLCs CAATevents and the Institute for Evidence-based Toxicology in Germany.